Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Telix to Explore PSMA-PET Imaging in Collaborations with EDAP and Profound | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Telix to Explore PSMA-PET Imaging in Collaborations with EDAP and Profound

Aim to advance the integration of molecular imaging into the evolving prostate cancer treatment landscape.

Author Image

By: Charlie Sternberg

Associate Editor, Contract Pharma

Telix Pharmaceuticals Limited will pursue collaborations with EDAP TMS S.A. and Profound Medical Corp., companies developing advanced minimally invasive and image-guided treatment ablative technologies for prostate cancer. Telix’ goal is to advance the integration of molecular imaging into the evolving prostate cancer treatment landscape to help inform clinical decision-making.

The collaborations will explore the investigational use of Telix’s PSMA-PET imaging agents Gozellix (kit for the preparation of gallium Ga 68 gozetotide) and Illuccix (kit for the preparation of gallium Ga 68 gozetotide) with robotic high-intensity focused ultrasound (HIFU), and other image-guided therapies designed to treat localized prostate cancer, such as transurethral ultrasound ablation (TULSA).

Telix’s intention is to work with select partners to explore how PSMA-PET imaging may support emerging therapy workflows, which aim to preserve healthy tissue and minimize the risk of side effects such as incontinence and impotence. Collaborative activities will focus on non-promotional scientific, educational, and research engagement.

“Precision medicine requires precision treatment strategies,” said Kevin Richardson, CEO, Telix Precision Medicine. “As disruptive technologies continue to transform prostate cancer care, we believe PSMA-PET imaging has the potential to play an important role in helping inform clinical decision-making across a range of minimally invasive and image-guided treatment approaches. We are excited to explore collaborations with market leaders in EDAP and Profound that may further advance personalized care for patients.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics